Determining the frequency and outcomes of neurological disorders associated with COVID-19 is imperative for understanding risks as well as recognition of emerging neurological disorders. We investigated the susceptibility and impact of SARS-CoV-2 infection among persons with premorbid neurological disorder rs, as well as the post-infection incidence of neurological sequelae in a case-control population-based cohort. Using health service data collected from March 1, 2020, to June 30, 2021, we constructed a cohort of SARS-CoV-2 RNA-positive (n=177,892) and -negative (n=177,800) adults who were age-, sex-, and comorbidity-matched and underwent RT- PCR testing at similar times. COVID-19 associated mortality rates were examined within the cohort. Neurological sequelae were analysed during the acute (less than three months) and the post-acute (three to nine months) phases post-infection. The risk of death was significantly greater in the SARS-CoV-2 RNA-positive (2,140 per 100,000 person years) compared to RNA-negative (922 per 100,000 person years) over a follow-up of 9 months, particularly amongst those with premorbid neurological disorders: adjusted odds ratios (aOR, 95% CI) in persons with a prior history of parkinsonism (1·65, 1·15-2·37), dementia (1·30, 1·11-1·52), seizures (1·91, 1·26-2·87), encephalopathy (1·82, 1·02-3·23), and stroke (1·74, 1·05-2·86). There was also a significantly increased risk for diagnosis of new neurological sequelae during the acute time phase after COVID-19 including encephalopathy (2·0, 1·10-3·64), dementia (1·36, 1·07-1·73), seizure (1·77, 1·22-2·56), and brain fog (1·96, 1·20-3·20). These risks persisted into the post-acute phase after COVID-19 during which inflammatory myopathy (2·57, 1·07-6·15) and coma (1·87, 1·22-2·87) also became significantly increased. Thus, persons with SARS-CoV-2 infection and premorbid neurological disorders are at greater risk of death while SARS-CoV-2 infection was complicated by increased risk of new onset neurological disorders in both the acute and post-acute phases of COVID-19.
Keywords: COVID-19; SARS-CoV-2; case-control; neurological complications; neurological disorders; population epidemiology.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.